Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

In Vivo’s Deals Of The Year 2020: Cast Your Vote!

Jan 14 2021

• By Lucie Ellis-Taitt

In Vivo's Deal of the Year

Related Content

UK First To Authorize Pfizer/BioNTech COVID-19 Vaccine

Dec 02 2020

Finance Watch: AbCellera, 4DMT, Nanobiotix IPOs Bring In $775m Combined

Dec 12 2020

Biogen Bets Big To Bag Sage Depression And Tremor Drugs

Nov 27 2020

J&J Seeks Command Position In FcRn Space With Momenta Buyout

Aug 19 2020

BMS Buys MyoKardia, Plans To Use Eliquis Experience To Grow Mavacamten

Oct 05 2020

Coronavirus Update: Gilead's Veklury Gets Full FDA Approval, Roche Partners With Atea

Oct 23 2020

AstraZeneca Likes Sound Of Silence's Science

Mar 25 2020

Gilead Calls Forty Seven Buyout Complementary To Kite, Other IO Efforts

Mar 02 2020

The Rise And Fall And Long-Term Rise Of Digitally Enabled Health Care

Nov 18 2020

Podcast: Exec Chat – Medtronic CMO On How COVID-19 Has Changed The Company – And Where It’s Headed

Dec 22 2020

Related Companies

Silence Therapeutics plc

AstraZeneca PLC

Sage Therapeutics, Inc.

Pfizer Inc.

BioNTech SE

Roche Holding AG

Atea Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.

AbCellera Biologics Inc.

Eli Lilly and Company

Neurogene Inc.

Olema Pharmaceuticals, Inc.

Royalty Pharma plc

Bristol Myers Squibb Company

MyoKardia, Inc.

Gilead Sciences, Inc.

Johnson & Johnson

Aimmune Therapeutics, Inc.

Additional Topics

Commercial Companies Deals Financing M & A Market Intelligence BioPharmaceutical Medical Device

More from Deal-Making

More from In Vivo

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window